Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Braendengen, 2008, Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer, J Clin Oncol, 26, 3687, 10.1200/JCO.2007.15.3858 Bosset, 2006, Chemotherapy with preoperative radiotherapy in rectal cancer, N Engl J Med, 355, 1114, 10.1056/NEJMoa060829 Erlandsson, 2017, Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial, Lancet Oncol, 18, 336, 10.1016/S1470-2045(17)30086-4 Gérard, 2006, Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203, J Clin Oncol, 24, 4620, 10.1200/JCO.2006.06.7629 Breugom, 2015, Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial, Ann Oncol, 26, 696, 10.1093/annonc/mdu560 Radu, 2008, Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study, Radiother Oncol, 87, 343, 10.1016/j.radonc.2007.11.025 Nilsson, 2013, Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer—the RAPIDO trial, BMC Cancer, 13, 279, 10.1186/1471-2407-13-279 van Dijk, 2013, Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer, Ann Oncol, 24, 1762, 10.1093/annonc/mdt124 van der Valk, 2020, Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - results of the international randomized RAPIDO-trial, Radiother Oncol, 147, 75, 10.1016/j.radonc.2020.03.011 Valentini, 2009, Multidisciplinary rectal cancer management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2), Radiother Oncol, 92, 148, 10.1016/j.radonc.2009.06.027 Brown, 2003, Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison, Radiology, 227, 371, 10.1148/radiol.2272011747 Dindo, 2004, Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann Surg, 240, 205, 10.1097/01.sla.0000133083.54934.ae Wittekind, 2009, A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status, Cancer, 115, 3483, 10.1002/cncr.24320 Bryant, 2012, Anterior resection syndrome, Lancet Oncol, 13, e403, 10.1016/S1470-2045(12)70236-X Koller, 2012, Competing risks and the clinical community: irrelevance or ignorance?, Stat Med, 31, 1089, 10.1002/sim.4384 Putter, 2007, Tutorial in biostatistics: competing risks and multi-state models, Stat Med, 26, 2389, 10.1002/sim.2712 Fokas, 2020, Outcome measures in multimodal rectal cancer trials, Lancet Oncol, 21, e252, 10.1016/S1470-2045(20)30024-3 Iveson, 2018, 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial, Lancet Oncol, 19, 562, 10.1016/S1470-2045(18)30093-7 Grothey, 2018, Duration of adjuvant chemotherapy for stage III colon cancer, N Engl J Med, 378, 1177, 10.1056/NEJMoa1713709 Bujko, 2015, Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: a meta-analysis of randomized trials comparing surgery ± a fluoropyrimidine and surgery + a fluoropyrimidine ± oxaliplatin, Eur J Surg Oncol, 41, 713, 10.1016/j.ejso.2015.03.233 Breugom, 2015, Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data, Lancet Oncol, 16, 200, 10.1016/S1470-2045(14)71199-4 Bujko, 2016, Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study, Ann Oncol, 27, 834, 10.1093/annonc/mdw062 Jin, 2017, The updated results for the phase 3 study of 5×5 Gy followed by chemotherapy in locally advanced rectal cancer (STELLAR trial), Int J Radiat Oncol Biol Phys, 99, e157 Peeters, 2007, The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma, Ann Surg, 246, 693, 10.1097/01.sla.0000257358.56863.ce Erlandsson, 2019, Tumour regression after radiotherapy for rectal cancer - results from the randomised Stockholm III trial, Radiother Oncol, 135, 178, 10.1016/j.radonc.2019.03.016 Garcia-Aguilar, 2015, Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial, Lancet Oncol, 16, 957, 10.1016/S1470-2045(15)00004-2 Marco, 2018, Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final results of a multicenter phase II trial, Dis Colon Rectum, 61, 1146, 10.1097/DCR.0000000000001207 Maas, 2010, Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data, Lancet Oncol, 11, 835, 10.1016/S1470-2045(10)70172-8 van der Valk, 2018, Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study, Lancet, 391, 2537, 10.1016/S0140-6736(18)31078-X Conroy, 2020, Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: final results of PRODIGE 23 phase III trial, a UNICANCER GI trial, Proc Am Soc Clin Oncol, 38 Fokas, 2019, Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ArO/AIO-12, J Clin Oncol, 37, 3212, 10.1200/JCO.19.00308 Viani, 2011, Evaluation of biologic effective dose and schedule of fractionation for preoperative radiotherapy for rectal cancer: meta-analyses and meta-regression, Int J Radiat Oncol Biol Phys, 80, 985, 10.1016/j.ijrobp.2010.03.008 Birgisson, 2007, Late adverse effects of radiation therapy for rectal cancer - a systematic overview, Acta Oncol, 46, 504, 10.1080/02841860701348670 Ngan, 2012, Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04, J Clin Oncol, 30, 3827, 10.1200/JCO.2012.42.9597 Bujko, 2006, Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer, Br J Surg, 93, 1215, 10.1002/bjs.5506 Beets-Tan, 2018, Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting, Eur Radiol, 28, 1465, 10.1007/s00330-017-5026-2 Marijnen, 2020, International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic, Radiother Oncol, 148, 213, 10.1016/j.radonc.2020.03.039